Kiniksa Pharmaceuticals News Releases https://investors.kiniksa.com/ Kiniksa Pharmaceuticals News Releases en Kiniksa Presents Preclinical Data on the GM-CSF Signaling Pathway in Temporal Arteries of GCA Patients at the Annual European Congress of Rheumatology https://investors.kiniksa.com/news-releases/news-release-details/kiniksa-presents-preclinical-data-gm-csf-signaling-pathway - Preclinical data support rationale for targeting GM-CSF in GCA – - Mavrilimumab shows biological effect on genes relevant to GCA pathophysiology in ex vivo cultures of GCA arteries – HAMILTON, Bermuda , June 12, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. Wed, 12 Jun 2019 07:30:00 -0400 Kiniksa Pharmaceuticals News Releases 7181 Kiniksa to Present Preclinical Data on the GM-CSF Signaling Pathway in Temporal Arteries of GCA Patients at EULAR 2019 https://investors.kiniksa.com/news-releases/news-release-details/kiniksa-present-preclinical-data-gm-csf-signaling-pathway HAMILTON, Bermuda , May 30, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today announced that Thu, 30 May 2019 16:01:00 -0400 Kiniksa Pharmaceuticals News Releases 7111 Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences https://investors.kiniksa.com/news-releases/news-release-details/kiniksa-pharmaceuticals-present-upcoming-investor-conferences HAMILTON, Bermuda , May 29, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the following investor conferences in June: Jefferies 2019 Global Healthcare Conference on Wednesday, June 5 th at 10:00 a.m. Eastern Time in New York, NY . Wed, 29 May 2019 16:01:00 -0400 Kiniksa Pharmaceuticals News Releases 7096 Kiniksa to Present Data on the Burden of Disease in Patients with Recurrent Pericarditis at the International Society for Pharmacoeconomics and Outcomes Research https://investors.kiniksa.com/news-releases/news-release-details/kiniksa-present-data-burden-disease-patients-recurrent HAMILTON, Bermuda , May 16, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, will present data from Thu, 16 May 2019 07:30:00 -0400 Kiniksa Pharmaceuticals News Releases 7066 Kiniksa Presents Clinical and Preclinical Data for KPL-716 at the 77th Annual Meeting of the Society for Investigative Dermatology https://investors.kiniksa.com/news-releases/news-release-details/kiniksa-presents-clinical-and-preclinical-data-kpl-716-77th - Data strengthen the scientific evidence for targeting OSMRβ and dual pathway inhibition of IL-31 and OSM via KPL-716 for the potential treatment of chronic pruritic diseases HAMILTON, Bermuda , May 13, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. Mon, 13 May 2019 07:30:00 -0400 Kiniksa Pharmaceuticals News Releases 7061 Kiniksa Reports First Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity https://investors.kiniksa.com/news-releases/news-release-details/kiniksa-reports-first-quarter-2019-financial-results-and – First patient dosed in Phase 2a trial of KPL-716 in prurigo nodularis – Upcoming presentations at SID, ISPOR and EULAR scientific conferences on KPL-716, rilonacept and mavrilimumab, respectively – Acquisition of KPL-404 (anti-CD40) complete; IND filing with FDA anticipated in 2H 2019 HAMILTON, Thu, 02 May 2019 07:30:00 -0400 Kiniksa Pharmaceuticals News Releases 7011 Kiniksa to Present Clinical and Preclinical Data for KPL-716 at the 77th Annual Meeting of the Society for Investigative Dermatology https://investors.kiniksa.com/news-releases/news-release-details/kiniksa-present-clinical-and-preclinical-data-kpl-716-77th HAMILTON, Bermuda , April 17, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today announced that Wed, 17 Apr 2019 16:25:00 -0400 Kiniksa Pharmaceuticals News Releases 6961 Kiniksa to Present KPL-404 Preclinical Data at the Keystone Symposia on Antibodies as Drugs https://investors.kiniksa.com/news-releases/news-release-details/kiniksa-present-kpl-404-preclinical-data-keystone-symposia HAMILTON, Bermuda , April 08, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today announced that Mon, 08 Apr 2019 16:01:00 -0400 Kiniksa Pharmaceuticals News Releases 6926 Kiniksa Presents Rilonacept Interim Phase 2 Clinical Data Poster at the American College of Cardiology’s 68th Annual Scientific Session https://investors.kiniksa.com/news-releases/news-release-details/kiniksa-presents-rilonacept-interim-phase-2-clinical-data-poster - Interim clinical data show reductions in both inflammation and reported pain throughout the treatment period - Enrollment is ongoing in RHAPSODY, Kiniksa’s pivotal Phase 3 trial of rilonacept in recurrent pericarditis HAMILTON, Bermuda , March 18, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Mon, 18 Mar 2019 07:30:00 -0400 Kiniksa Pharmaceuticals News Releases 6886 Kiniksa Reports Fourth Quarter and Full-Year 2018 Financial Results and Highlights Recent Corporate and Pipeline Activity https://investors.kiniksa.com/news-releases/news-release-details/kiniksa-reports-fourth-quarter-and-full-year-2018-financial – Enrollment and dosing of patients commenced in rilonacept pivotal Phase 3 trial – Enrollment and dosing of patients commenced in mavrilimumab global Phase 2 trial – KPL-716 advancing into two Phase 2 trials in 1H 2019; repeated-single-dose Phase 1b data expected in 2H 2019   – Additional interim Thu, 07 Mar 2019 07:30:00 -0500 Kiniksa Pharmaceuticals News Releases 6856